NDC 49401-088 – Benlysta
Belimumab 200 mg/mL · Solution · Subcutaneous
Product NDC49401-088
Product details
- Brand name
- Benlysta
- Generic name
- Belimumab
- Labeler
- GlaxoSmithKline LLC
- Dosage form
- Solution
- Route
- Subcutaneous
- Marketing category
- BLA · BLA761043
- Marketed since
- July 20, 2017
- Listing expires
- December 31, 2027
- Pharmacologic class
- B Lymphocyte Stimulator-specific Inhibitor
Active ingredients
- Belimumab 200 mg/mL
Package NDC codes (5)
| Package NDC | Description | Since |
|---|---|---|
| 49401-088-02 | 1 SYRINGE in 1 CARTON (49401-088-02) / 1 mL in 1 SYRINGE (49401-088-01) | Jul 20, 2017 |
| 49401-088-35 | 4 SYRINGE in 1 CARTON (49401-088-35) / 1 mL in 1 SYRINGE (49401-088-01) | Jul 20, 2017 |
| 49401-088-47 | 4 SYRINGE in 1 CARTON (49401-088-47) / 1 mL in 1 SYRINGE (49401-088-42) | Jul 20, 2017 |
| 49401-088-50 | 1 SYRINGE in 1 CARTON (49401-088-50) / 1 mL in 1 SYRINGE (49401-088-42) | Jul 20, 2017 |
| 49401-088-61 sample | 1 SYRINGE in 1 CARTON (49401-088-61) / 1 mL in 1 SYRINGE | Jun 2, 2020 |
Recalls mentioning this NDC
- D-0540-2025 Jul 30, 2025 · Class II
CGMP Deviations; potential temperature excursions due to transit delays